FDA slaps a hold on Solid Bio's gene therapy for Duchenne MD in wake of safety alert
Just a few weeks after Solid Biosciences $SLDB put out an 11th hour notice that its gene therapy for Duchenne muscular dystrophy had been put on a partial clinical hold due to safety concerns, just ahead of its $125 million IPO, the biotech is back Wednesday evening with the news that the agency has now halted the study in the wake of an adverse reaction to the therapy by the first patient in the trial.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
